Carl Zeiss Meditec AG has entered into an agreement to acquire all shares of Dutch Ophthalmic Research Center, according to a press release.
The acquisition will cost approximately 985 million euros (approximately US$1.073 billion) and is expected to be complete in the first half of 2024.
DORC’s assets include the Eva Nexus platform, which previously received FDA 510(k) clearance for subretinal injection and is designed to allow for the performance of a variety of vitreoretinal, cataract and combined procedures on a single system.
The acquisition will build Zeiss’ ophthalmic